scholarly journals Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson’s disease diagnosis

PLoS ONE ◽  
2018 ◽  
Vol 13 (11) ◽  
pp. e0206536 ◽  
Author(s):  
Marcia Cristina T. dos Santos ◽  
Dieter Scheller ◽  
Claudia Schulte ◽  
Irene R. Mesa ◽  
Peter Colman ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Early Stage ◽  
Disease Diagnosis ◽  
Cerebrospinal Fluid Proteins ◽  
Potential Biomarkers

scholarly journals Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson’s Disease

Metabolites ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 14
Author(s):  
Petr G. Lokhov ◽  
Dmitry L. Maslov ◽  
Steven Lichtenberg ◽  
Oxana P. Trifonova ◽  
Elena E. Balashova
Keyword(s):  
Parkinson’S Disease ◽  
Molecular Weight ◽  
Parkinson's Disease ◽  
High Resolution Mass Spectrometry ◽  
Early Stage ◽  
Disease Diagnosis ◽  
The Body ◽  
Low Molecular Weight ◽  
Low Molecular Weight Compounds

A laboratory-developed test (LDT) is a type of in vitro diagnostic test that is developed and used within a single laboratory. The holistic metabolomic LDT integrating the currently available data on human metabolic pathways, changes in the concentrations of low-molecular-weight compounds in the human blood during diseases and other conditions, and their prevalent location in the body was developed. That is, the LDT uses all of the accumulated metabolic data relevant for disease diagnosis and high-resolution mass spectrometry with data processing by in-house software. In this study, the LDT was applied to diagnose early-stage Parkinson’s disease (PD), which currently lacks available laboratory tests. The use of the LDT for blood plasma samples confirmed its ability for such diagnostics with 73% accuracy. The diagnosis was based on relevant data, such as the detection of overrepresented metabolite sets associated with PD and other neurodegenerative diseases. Additionally, the ability of the LDT to detect normal composition of low-molecular-weight compounds in blood was demonstrated, thus providing a definition of healthy at the molecular level. This LDT approach as a screening tool can be used for the further widespread testing for other diseases, since ‘omics’ tests, to which the metabolomic LDT belongs, cover a variety of them.

scholarly journals miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease

Oncotarget ◽  
2018 ◽  
Vol 9 (25) ◽  
pp. 17455-17465 ◽  
Author(s):  
Marcia Cristina T. dos Santos ◽  
Miguel Arturo Barreto-Sanz ◽  
Bruna Renata S. Correia ◽  
Rosie Bell ◽  
Catherine Widnall ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Early Stage ◽  
Diagnostic Tools

scholarly journals AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson’s disease diagnosis

2017 ◽  
Vol 8 (9) ◽  
pp. 696-700 ◽  
Author(s):  
Hongli Zhao ◽  
Jue Zhao ◽  
Jiapeng Hou ◽  
Siqing Wang ◽  
Yu Ding ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Potential Application ◽  
Disease Diagnosis ◽  
Alpha Synuclein

Cerebrospinal fluid levels of chromogranin A in the treatment-naïve early stage Parkinson’s disease: a pilot study

2013 ◽  
Vol 120 (11) ◽  
pp. 1559-1563 ◽  
Author(s):  
Michaela Kaiserová ◽  
Hana Přikrylová Vranová ◽  
David Stejskal ◽  
Kateřina Menšíková ◽  
Petr Kaňovský
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Pilot Study ◽  
Chromogranin A ◽  
Early Stage ◽  
Cerebrospinal Fluid Levels ◽  
Treatment Naïve ◽  
Fluid Levels

scholarly journals Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders

2016 ◽  
Vol 139 ◽  
pp. 290-317 ◽  
Author(s):  
Brit Mollenhauer ◽  
Lucilla Parnetti ◽  
Irena Rektorova ◽  
Milica G. Kramberger ◽  
Maria Pikkarainen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Cerebrospinal Fluid Proteins

scholarly journals Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease

2015 ◽  
Vol 78 (6) ◽  
pp. 1000-1004 ◽  
Author(s):  
Angela Pyle ◽  
Rebecca Brennan ◽  
Marzena Kurzawa-Akanbi ◽  
Alison Yarnall ◽  
Anais Thouin ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cerebrospinal Fluid ◽  
Mitochondrial Dna ◽  
Early Stage
Sign in / Sign up

Export Citation Format

Share Document